Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
CytoDyn Inc CYDY
(Total Views: 797)
Posted On: 12/10/2020 9:13:21 AM
Post# of 155844
Avatar
Posted By: TechGuru
I don't want to add fuel to the fire. My position has been always clear (and no, I am not a short ):

https://investorshangout.com/post/view?id=597...z6gEHC2Zlg

Quote:
Agreed, I have been following BP (the doctor) studies, publications & experiments and consider not having him working actively with us one of the main missteps of NP .

His research and voice would leverage Vyrologix and CYDY standing in the scientific community many times.

Hope in the future some bridges can still be build .



Now: few hours ago Dr. Patterson was asked:

133067765_BruceTweet.jpg

This is precisely why he is critical : a badly designed trial without proper support and knowledge will lead to better than expected results. A good one to approval.

Please remember what happened with our M/M trial. We would be selling Vyrologix as we speak if we had designed this trial better (I am not blaming anybody as little was known then).

The critical word is KNOW . Please tell me: Who knows better than BP about Long Haulers, possible trial design ??? measurements ??? timing of reactions, check points ??? possible outcomes ??? shortcomings ??? combinations ??? End-points ????

His knowledge is worth Billions (yes with B ). So, with all due respect, this is not a short attack, the mail might be exaggerated or whatever, but the content remains valid imo.

Bruce Patterson would add a huge amount of value to our SP and to the COVID/CANCER/HIV sufferers all over. He has the knowledge, we have the drug.

And no, this is not an attack on NP. I have been a staunch supporter of him in spite of his obvious shortcomings (we all have them).

He just made a big mistake in the case of Bruce Patterson. I am not privy as of what happened. I don't think there is a case of dishonestly (on either side) but rather a case of money or personalities.

I believe there should be reconsiderations on both sides as both will/would greatly benefit from a synergistic approach.

We have a long road ahead and having such a scientist on-board would be definitely a big plus as we still need to do lots of research and don't have in-house capabilities. Saying that we need only drug commercialization capabilities in such a complex world is just wrong-headed.




















(15)
(1)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site